MMC
SRPT icon

Mizuho Markets Cayman’s Sarepta Therapeutics SRPT Stock Holding History

Mizuho Markets Cayman’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-259,809
Closed -$35.8M – 134
2023
Q1 		$35.8M Buy
+259,809
New +$33.7M 1.44% 17

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mizuho Markets Cayman's SRPT Position: Q2 2023 in Review

Mizuho Markets Cayman sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 259,809 shares — an estimated $35.8M sold.

Mizuho Markets Cayman first reported a position in SRPT in Q1 2023 and held it in 1 quarter. The position peaked at $35.8M in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Mizuho Markets Cayman reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Mizuho Markets Cayman sold 259,809 Sarepta Therapeutics shares in Q2 2023, an estimated $35.8M.
  • Mizuho Markets Cayman first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 1 quarter.
  • Mizuho Markets Cayman's Sarepta Therapeutics position peaked at $35.8M in Q1 2023.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Mizuho Markets Cayman's 13F filing for Q2 2023, filed 9 Aug 2023.